06/13/2026
🧬 Japan has developed a blood test that detects 13 types of cancer from a single drop — with accuracy that rivals conventional diagnostic imaging.
Japan's national cancer screening program reaches millions of people annually — but its effectiveness is limited by the cost, discomfort, and logistical complexity of conventional screening modalities. Colonoscopy for colorectal cancer. Mammography for breast cancer. CT scanning for lung cancer. Each requires specialized equipment, trained operators, patient preparation, and significant time commitment.
The National Cancer Center Japan — in partnership with Toray Industries and Kyoto University — has developed a liquid biopsy blood test based on microRNA profiling that simultaneously screens for 13 cancer types from a single 1 mL blood draw. The test analyzes 2,565 microRNA species in the blood sample, comparing the expression profile against a database of confirmed cancer and non-cancer cases to identify patterns associated with specific cancer types.
Clinical validation in a prospective cohort study of 4,200 participants — approximately half with confirmed cancer diagnoses — demonstrated detection rates exceeding 85% for the 13 cancer types included, with false positive rates below 10%. The combined detection performance represents a multi-cancer screening capability that no conventional single-cancer test can approach in efficiency.
Japan's Ministry of Health, Labour and Welfare has granted expedited review status to the microRNA cancer screening test — recognizing that its potential public health impact justifies faster regulatory processing. Deployment through Japan's national health system checkup program is targeted for 2027.
National Cancer Center Japan — Toray Industries — 2024